Gilead Sciences, Inc. (GILD) on Tuesday announced that Health Canada has approved Lyvdelzi for the treatment of adults with primary biliary cholangitis (PBC), a rare, chronic autoimmune liver disease that gradually destroys the liver's bile ducts.
Lyvdelzi is approved for use in combination with ursodeoxycholic acid (UDCA) in patients with an inadequate response to UDCA alone, or as monotherapy in patients unable to tolerate UDCA.
The market authorization has been granted with conditions, pending the results of clinical trials to confirm its therapeutic benefit. The conditional approval was primarily based on positive data from the Phase 3 RESPONSE study.
Gilead stock was down 0.32% in pre-market at $122.71.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.